The primary goal of our study was to validate the safety and feasibility of the adoptive transfer of autologous iNKT cells consolidated with PD-1+CD8+ T cells expanded in vitro as a potential treatment for patients with pancreatic cancer. Here, CD8A is linked to familial pancreatic carcinoma.